カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の神経筋遮断薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Neuromuscular Blocking Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19456）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19456
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：97
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の神経筋遮断薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

神経筋遮断薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の神経筋遮断薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

神経筋遮断薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・無極性剤、脱極性剤

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他

世界の神経筋遮断薬市場の主要な市場プレーヤーは以下のとおりです。
・Hikma Pharmaceuticals、Merck、Novartis、Bayer、Pfizer、AbbVie、GSK

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、神経筋遮断薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な神経筋遮断薬メーカーの企業概要、2019年～2022年までの神経筋遮断薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な神経筋遮断薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別神経筋遮断薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの神経筋遮断薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での神経筋遮断薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および神経筋遮断薬の産業チェーンを掲載しています。
・第13、14、15章では、神経筋遮断薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 神経筋遮断薬の概要
- 種類別分析（2017年vs2021年vs2028年）：無極性剤、脱極性剤
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他
- 世界の神経筋遮断薬市場規模・予測
- 世界の神経筋遮断薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Hikma Pharmaceuticals、Merck、Novartis、Bayer、Pfizer、AbbVie、GSK
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：無極性剤、脱極性剤
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局、その他
・神経筋遮断薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・神経筋遮断薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・神経筋遮断薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・神経筋遮断薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・神経筋遮断薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Neuromuscular Blocking Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuromuscular Blocking Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacy accounting for % of the Neuromuscular Blocking Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Non-polarizing Agents segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuromuscular Blocking Drug include Hikma Pharmaceuticals, Merck, Novartis, Bayer, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuromuscular Blocking Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Non-polarizing Agents
Depolarizing Agents
Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
The key market players for global Neuromuscular Blocking Drug market are listed below:
Hikma Pharmaceuticals
Merck
Novartis
Bayer
Pfizer
AbbVie
GSK
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuromuscular Blocking Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuromuscular Blocking Drug, with price, sales, revenue and global market share of Neuromuscular Blocking Drug from 2019 to 2022.
Chapter 3, the Neuromuscular Blocking Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuromuscular Blocking Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuromuscular Blocking Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromuscular Blocking Drug.
Chapter 13, 14, and 15, to describe Neuromuscular Blocking Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Neuromuscular Blocking Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuromuscular Blocking Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Non-polarizing Agents
1.2.3 Depolarizing Agents
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuromuscular Blocking Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Drug Market Size & Forecast
1.4.1 Global Neuromuscular Blocking Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuromuscular Blocking Drug Sales in Volume (2017-2028)
1.4.3 Global Neuromuscular Blocking Drug Price (2017-2028)
1.5 Global Neuromuscular Blocking Drug Production Capacity Analysis
1.5.1 Global Neuromuscular Blocking Drug Total Production Capacity (2017-2028)
1.5.2 Global Neuromuscular Blocking Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuromuscular Blocking Drug Market Drivers
1.6.2 Neuromuscular Blocking Drug Market Restraints
1.6.3 Neuromuscular Blocking Drug Trends Analysis
2 Manufacturers Profiles
2.1 Hikma Pharmaceuticals
2.1.1 Hikma Pharmaceuticals Details
2.1.2 Hikma Pharmaceuticals Major Business
2.1.3 Hikma Pharmaceuticals Neuromuscular Blocking Drug Product and Services
2.1.4 Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Neuromuscular Blocking Drug Product and Services
2.2.4 Merck Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Neuromuscular Blocking Drug Product and Services
2.3.4 Novartis Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Neuromuscular Blocking Drug Product and Services
2.4.4 Bayer Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Neuromuscular Blocking Drug Product and Services
2.5.4 Pfizer Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 AbbVie
2.6.1 AbbVie Details
2.6.2 AbbVie Major Business
2.6.3 AbbVie Neuromuscular Blocking Drug Product and Services
2.6.4 AbbVie Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 GSK
2.7.1 GSK Details
2.7.2 GSK Major Business
2.7.3 GSK Neuromuscular Blocking Drug Product and Services
2.7.4 GSK Neuromuscular Blocking Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neuromuscular Blocking Drug Breakdown Data by Manufacturer
3.1 Global Neuromuscular Blocking Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuromuscular Blocking Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuromuscular Blocking Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Neuromuscular Blocking Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Neuromuscular Blocking Drug Manufacturer Market Share in 2021
3.5 Global Neuromuscular Blocking Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuromuscular Blocking Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuromuscular Blocking Drug Market Size by Region
4.1.1 Global Neuromuscular Blocking Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Neuromuscular Blocking Drug Revenue by Region (2017-2028)
4.2 North America Neuromuscular Blocking Drug Revenue (2017-2028)
4.3 Europe Neuromuscular Blocking Drug Revenue (2017-2028)
4.4 Asia-Pacific Neuromuscular Blocking Drug Revenue (2017-2028)
4.5 South America Neuromuscular Blocking Drug Revenue (2017-2028)
4.6 Middle East and Africa Neuromuscular Blocking Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neuromuscular Blocking Drug Sales in Volume by Type (2017-2028)
5.2 Global Neuromuscular Blocking Drug Revenue by Type (2017-2028)
5.3 Global Neuromuscular Blocking Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neuromuscular Blocking Drug Sales in Volume by Application (2017-2028)
6.2 Global Neuromuscular Blocking Drug Revenue by Application (2017-2028)
6.3 Global Neuromuscular Blocking Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neuromuscular Blocking Drug Sales by Type (2017-2028)
7.2 North America Neuromuscular Blocking Drug Sales by Application (2017-2028)
7.3 North America Neuromuscular Blocking Drug Market Size by Country
7.3.1 North America Neuromuscular Blocking Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Neuromuscular Blocking Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuromuscular Blocking Drug Sales by Type (2017-2028)
8.2 Europe Neuromuscular Blocking Drug Sales by Application (2017-2028)
8.3 Europe Neuromuscular Blocking Drug Market Size by Country
8.3.1 Europe Neuromuscular Blocking Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuromuscular Blocking Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neuromuscular Blocking Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Neuromuscular Blocking Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Neuromuscular Blocking Drug Market Size by Region
9.3.1 Asia-Pacific Neuromuscular Blocking Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuromuscular Blocking Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neuromuscular Blocking Drug Sales by Type (2017-2028)
10.2 South America Neuromuscular Blocking Drug Sales by Application (2017-2028)
10.3 South America Neuromuscular Blocking Drug Market Size by Country
10.3.1 South America Neuromuscular Blocking Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Neuromuscular Blocking Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuromuscular Blocking Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Neuromuscular Blocking Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Neuromuscular Blocking Drug Market Size by Country
11.3.1 Middle East & Africa Neuromuscular Blocking Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuromuscular Blocking Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neuromuscular Blocking Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuromuscular Blocking Drug
12.3 Neuromuscular Blocking Drug Production Process
12.4 Neuromuscular Blocking Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuromuscular Blocking Drug Typical Distributors
13.3 Neuromuscular Blocking Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Neuromuscular Blocking Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuromuscular Blocking Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Hikma Pharmaceuticals Major Business
Table 5. Hikma Pharmaceuticals Neuromuscular Blocking Drug Product and Services
Table 6. Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Merck Basic Information, Manufacturing Base and Competitors
Table 8. Merck Major Business
Table 9. Merck Neuromuscular Blocking Drug Product and Services
Table 10. Merck Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novartis Basic Information, Manufacturing Base and Competitors
Table 12. Novartis Major Business
Table 13. Novartis Neuromuscular Blocking Drug Product and Services
Table 14. Novartis Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Bayer Basic Information, Manufacturing Base and Competitors
Table 16. Bayer Major Business
Table 17. Bayer Neuromuscular Blocking Drug Product and Services
Table 18. Bayer Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Neuromuscular Blocking Drug Product and Services
Table 22. Pfizer Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. AbbVie Basic Information, Manufacturing Base and Competitors
Table 24. AbbVie Major Business
Table 25. AbbVie Neuromuscular Blocking Drug Product and Services
Table 26. AbbVie Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. GSK Basic Information, Manufacturing Base and Competitors
Table 28. GSK Major Business
Table 29. GSK Neuromuscular Blocking Drug Product and Services
Table 30. GSK Neuromuscular Blocking Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Neuromuscular Blocking Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Neuromuscular Blocking Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Neuromuscular Blocking Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Neuromuscular Blocking Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Neuromuscular Blocking Drug Production Site of Key Manufacturer
Table 36. Neuromuscular Blocking Drug New Entrant and Capacity Expansion Plans
Table 37. Neuromuscular Blocking Drug Mergers & Acquisitions in the Past Five Years
Table 38. Global Neuromuscular Blocking Drug Sales by Region (2017-2022) & (K Units)
Table 39. Global Neuromuscular Blocking Drug Sales by Region (2023-2028) & (K Units)
Table 40. Global Neuromuscular Blocking Drug Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Neuromuscular Blocking Drug Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 43. Global Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 44. Global Neuromuscular Blocking Drug Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Neuromuscular Blocking Drug Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Neuromuscular Blocking Drug Price by Type (2017-2022) & (US$/Unit)
Table 47. Global Neuromuscular Blocking Drug Price by Type (2023-2028) & (US$/Unit)
Table 48. Global Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 49. Global Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 50. Global Neuromuscular Blocking Drug Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Neuromuscular Blocking Drug Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Neuromuscular Blocking Drug Price by Application (2017-2022) & (US$/Unit)
Table 53. Global Neuromuscular Blocking Drug Price by Application (2023-2028) & (US$/Unit)
Table 54. North America Neuromuscular Blocking Drug Sales by Country (2017-2022) & (K Units)
Table 55. North America Neuromuscular Blocking Drug Sales by Country (2023-2028) & (K Units)
Table 56. North America Neuromuscular Blocking Drug Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Neuromuscular Blocking Drug Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 59. North America Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 60. North America Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 61. North America Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 62. Europe Neuromuscular Blocking Drug Sales by Country (2017-2022) & (K Units)
Table 63. Europe Neuromuscular Blocking Drug Sales by Country (2023-2028) & (K Units)
Table 64. Europe Neuromuscular Blocking Drug Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Neuromuscular Blocking Drug Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 67. Europe Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 68. Europe Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 69. Europe Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Neuromuscular Blocking Drug Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Neuromuscular Blocking Drug Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Neuromuscular Blocking Drug Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Neuromuscular Blocking Drug Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 78. South America Neuromuscular Blocking Drug Sales by Country (2017-2022) & (K Units)
Table 79. South America Neuromuscular Blocking Drug Sales by Country (2023-2028) & (K Units)
Table 80. South America Neuromuscular Blocking Drug Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Neuromuscular Blocking Drug Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 83. South America Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 84. South America Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 85. South America Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Neuromuscular Blocking Drug Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Neuromuscular Blocking Drug Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Neuromuscular Blocking Drug Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Neuromuscular Blocking Drug Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Neuromuscular Blocking Drug Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Neuromuscular Blocking Drug Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Neuromuscular Blocking Drug Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Neuromuscular Blocking Drug Sales by Application (2023-2028) & (K Units)
Table 94. Neuromuscular Blocking Drug Raw Material
Table 95. Key Manufacturers of Neuromuscular Blocking Drug Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Neuromuscular Blocking Drug Typical Distributors
Table 99. Neuromuscular Blocking Drug Typical Customers
List of Figures
Figure 1. Neuromuscular Blocking Drug Picture
Figure 2. Global Neuromuscular Blocking Drug Revenue Market Share by Type in 2021
Figure 3. Non-polarizing Agents
Figure 4. Depolarizing Agents
Figure 5. Global Neuromuscular Blocking Drug Revenue Market Share by Application in 2021
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Pharmacy
Figure 9. Others
Figure 10. Global Neuromuscular Blocking Drug Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Neuromuscular Blocking Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Neuromuscular Blocking Drug Sales (2017-2028) & (K Units)
Figure 13. Global Neuromuscular Blocking Drug Price (2017-2028) & (US$/Unit)
Figure 14. Global Neuromuscular Blocking Drug Production Capacity (2017-2028) & (K Units)
Figure 15. Global Neuromuscular Blocking Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Neuromuscular Blocking Drug Market Drivers
Figure 17. Neuromuscular Blocking Drug Market Restraints
Figure 18. Neuromuscular Blocking Drug Market Trends
Figure 19. Global Neuromuscular Blocking Drug Sales Market Share by Manufacturer in 2021
Figure 20. Global Neuromuscular Blocking Drug Revenue Market Share by Manufacturer in 2021
Figure 21. Neuromuscular Blocking Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Neuromuscular Blocking Drug Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Neuromuscular Blocking Drug Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Neuromuscular Blocking Drug Sales Market Share by Region (2017-2028)
Figure 25. Global Neuromuscular Blocking Drug Revenue Market Share by Region (2017-2028)
Figure 26. North America Neuromuscular Blocking Drug Revenue (2017-2028) & (USD Million)
Figure 27. Europe Neuromuscular Blocking Drug Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Neuromuscular Blocking Drug Revenue (2017-2028) & (USD Million)
Figure 29. South America Neuromuscular Blocking Drug Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Neuromuscular Blocking Drug Revenue (2017-2028) & (USD Million)
Figure 31. Global Neuromuscular Blocking Drug Sales Market Share by Type (2017-2028)
Figure 32. Global Neuromuscular Blocking Drug Revenue Market Share by Type (2017-2028)
Figure 33. Global Neuromuscular Blocking Drug Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 35. Global Neuromuscular Blocking Drug Revenue Market Share by Application (2017-2028)
Figure 36. Global Neuromuscular Blocking Drug Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Neuromuscular Blocking Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 39. North America Neuromuscular Blocking Drug Sales Market Share by Country (2017-2028)
Figure 40. North America Neuromuscular Blocking Drug Revenue Market Share by Country (2017-2028)
Figure 41. United States Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Neuromuscular Blocking Drug Sales Market Share by Type (2017-2028)
Figure 45. Europe Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 46. Europe Neuromuscular Blocking Drug Sales Market Share by Country (2017-2028)
Figure 47. Europe Neuromuscular Blocking Drug Revenue Market Share by Country (2017-2028)
Figure 48. Germany Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Neuromuscular Blocking Drug Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Neuromuscular Blocking Drug Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Neuromuscular Blocking Drug Revenue Market Share by Region (2017-2028)
Figure 57. China Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Neuromuscular Blocking Drug Sales Market Share by Type (2017-2028)
Figure 64. South America Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 65. South America Neuromuscular Blocking Drug Sales Market Share by Country (2017-2028)
Figure 66. South America Neuromuscular Blocking Drug Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Neuromuscular Blocking Drug Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Neuromuscular Blocking Drug Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Neuromuscular Blocking Drug Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Neuromuscular Blocking Drug Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Neuromuscular Blocking Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Neuromuscular Blocking Drug in 2021
Figure 78. Manufacturing Process Analysis of Neuromuscular Blocking Drug
Figure 79. Neuromuscular Blocking Drug Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のブロッキングペプチド市場2022年：市場規模予測（～2028年）
  • 世界のトランジェントブロッキングユニット（TBU）市場2022年：市場規模予測（～2028年）
  • ポアブロッキング耐水性混和剤のグローバル市場展望 2023年-2029年：無機化合物、有機化合物、複合材料
  • 世界の止水テープ＆糸市場2022年：市場規模予測（～2028年）
  • 世界のシリコーンアンチブロッキング剤市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19456 )"世界の神経筋遮断薬市場2022年：市場規模予測（～2028年）" (英文：Global Neuromuscular Blocking Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。